Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Sleep Health. 2017 Sep 28;4(1):20–26. doi: 10.1016/j.sleh.2017.08.006

Sleep Apnea and Pesticide Exposure in a Study of US Farmers

Brittney O Baumert 1, Megan Ulmer Carnes 1, Jane A Hoppin 2, Chandra L Jackson 1, Dale P Sandler 1, Laura Beane Freeman 3, Paul K Henneberger 4, David M Umbach 5, Srishti Shrestha 1, Stuart Long 6, Stephanie J London 1
PMCID: PMC5771434  NIHMSID: NIHMS909077  PMID: 29332674

Abstract

Introduction

Carbamate and organophosphate pesticides inhibit acetylcholinesterase and poisoning leads to respiratory depression. Thus, involvement in sleep apnea is plausible, but no data exist at lower levels of exposure. Other pesticides could impact sleep apnea by different mechanisms but have not been studied. Our study examines the associations between pesticide exposure and sleep apnea among pesticide applicators from a US farming population.

Participants and Methods

We analyzed data from 1,569 male pesticide applicators, mostly farmers, from an asthma case-control study nested within the prospective Agricultural Health Study. On questionnaires, participants reported use of specific pesticides and physician diagnosis plus prescribed treatments for sleep apnea. We used multivariable logistic regression to estimate associations between ever use of 63 pesticides and sleep apnea (234 cases, 1,335 non-cases).

Results

The most notable association was for carbofuran, a carbamate, (100 exposed cases, Odds Ratio (OR): 1.83, 95% Confidence Interval (CI) 1.34–2.51, P= 0.0002). Carbofuran use began before reported onset of sleep apnea in all cases.

Discussion

This study adds to the known adverse health outcomes of exposure to carbofuran, a pesticide cancelled in the US in 2009 for most agricultural purposes but persists in the environment and remains in use in some other countries.

Conclusions

We conducted the first epidemiological study investigating the association of pesticide exposure and sleep apnea. Our results in a male agricultural population suggests that exposure to carbofuran is positively associated with sleep apnea.

Keywords: Pesticides, Sleep Apnea, Carbofuran, Carbamates, Sleep Disorder Breathing, Agriculture

Introduction

Sleep-disordered breathing is characterized by instantaneous cessations in the rhythm of breathing (apneas) or momentary or prolonged reduction in the amplitude of breathing (hypopneas) (1). Sleep apneas and hypopneas can be caused by obstruction of the upper airway (obstructive), by reduced respiratory motor neuron function (central) or reflect mixed obstructive and central etiologies (1). Most sleep apnea-hypopnea events result from anatomical anomalies combined with a disturbance in the neurochemical control of the upper airway musculature (13). The neurotransmitter acetylcholine influences the function of upper airway motor neurons that control breathing during wakefulness and sleep (4).

Sleep apnea is a major contributor to morbidity, mortality, and reduced quality of life (1). In men, obstructive sleep apnea prevalence has been estimated at 3.3% with highest rates at ages 45–64 (5). Risk factors include increasing age, male gender, central obesity, craniofacial and upper airway abnormalities, cardiovascular disease, and diabetes. Central sleep apnea accounts for under five percent of patients presenting for sleep apnea evaluation (5, 6). Obstructive and central sleep apnea can co-occur, but there are distinct risk factors for central apnea including heart failure, stroke, high altitude, and opioid medication use (6). Data on environmental contributors to sleep apnea are few. Associations with air pollutants were identified in two recent population based studies (7, 8) an increased risk was reported in World Trade Center-exposed rescue or recovery workers (9). Two smaller studies have reported associations with solvent exposure (10, 11).

Both organophosphate and carbamate pesticides act by inhibiting acetylcholinesterase, an enzyme that hydrolyzes acetylcholine. Therefore, these agents can interfere with neuronal function, including control of respiration (4). In pesticide poisoning, respiratory depression occurs and may be fatal (12, 13). In animal studies, exposure to these pesticides elicits a spectrum of neurochemical, neurophysiological, and neurobehavioral deficits including respiratory depression and interference with sleep-wake cycles (14). Thus, exposure to pesticides that inhibit acetylcholinesterase is potentially relevant to sleep apnea in humans. Pesticides in other chemical classes are also neurotoxic and could theoretically be relevant to sleep apnea (15). Recent data suggest that carbamates can interact with the melatonin receptor (16) and that melatonin may play a role in sleep apnea (1618) providing an alternative, or complementary mechanism for carbamates to impact this disorder.

No epidemiological studies exist of sleep apnea in relation to pesticide exposure. We aimed to address this gap by investigating associations between sleep apnea and pesticide exposure among male pesticide applicators in the Agricultural Lung Health Study (ALHS).

Participants and Methods

Study population

The Agricultural Lung Health Study (ALHS) is a case-control study of current asthma nested within the prospective Agricultural Health Study (AHS). The AHS enrolled pesticide applicators applying for, or renewing, pesticide-use licenses in North Carolina and Iowa (19) along with their spouses in 1993–1997. The ALHS identified potential asthma cases and non-cases among respondents to an AHS follow-up telephone interview conducted 2005–2010 (24,171 pesticide applicators, 19,959 spouses). The Institutional Review Board of the National Institute of Environmental Health Sciences approved the study. All participants provided informed consent.

Details of ALHS enrollment have been published (20, 21). Briefly, we enrolled 3,301 ALHS participants between 2009 and 2013 (1,223 asthma cases; response rate=51.7%, and 2,078 non-cases; response rate=50.0%). We included three categories of asthma cases: doctor diagnosed current asthma (n=876), potential undiagnosed asthma based on current asthma symptoms and medication use in non-smokers (n=309), and overlapping diagnoses of current asthma and either chronic obstructive pulmonary disease (COPD) or emphysema in non-smokers (n=38). Non-cases were randomly selected from those without the above conditions. We analyzed only the 1,596 male pesticide applicators; 97% of pesticide applicators were men.

Sleep apnea assessment

Information on physician-diagnosed sleep apnea came from the ALHS computer-assisted telephone interview. We classified participants who reported ‘yes’ to “Have you ever been told by a doctor that you have sleep apnea?” and ‘yes’ to one of four possible sleep apnea treatments (“CPAP”, “surgery”, “bi-level”, or “other oral device”) as sleep apnea cases (n=236). Requiring treatment in the definition increases reliability of this self-reported outcome (22). Participants reporting ‘yes’ to physician-diagnosed sleep apnea but not reporting a treatment for sleep apnea were excluded from analysis (n=49). Otherwise individuals were classified as non-cases (n=1360).

Assessment of Pesticide Exposure

On earlier AHS questionnaires (www.aghealth.nih.gov) individuals provided names of chemicals used ever in their lifetimes (Phase One, 1993–1997), in the most recent farming season (Phase Two, 1999–2003), and since last study contact (Phase Three, 2005–2010). Reported names were linked to pesticide active ingredient names using the Environmental Protection Agency (EPA) Pesticide Classification Code (23). We analyzed the 63 pesticides reported by >1% of applicators at Phase Three that were also reported by at least 5 (of 236) sleep apnea cases. The 63 pesticides included 40 herbicides and plant growth regulators, 19 insecticides, 3 fungicides, and 1 rodenticide.

For 22 of the 63 pesticides, we had data on lifetime days of exposure, from the AHS Phase One enrollment questionnaire, to assess dose-response to individual pesticides (23). We divided lifetime days of use into approximate tertiles for comparison with never users.

Statistical analyses

Using logistic regression, we estimated odds ratios and 95% confidence intervals for both ever-never pesticide exposure and lifetime days of pesticide exposure in relation to sleep apnea. Consistent with previous AHS analyses, we included continuous age and state (North Carolina or Iowa) in all models. We additionally included asthma status, the design variable for selection of ALHS participants.

We evaluated as potential covariates additional variables implicated in sleep apnea etiology from the literature including body mass index (BMI, continuous), history of diabetes, cardiovascular disease, hypertension, alcohol use (24-hour recall), caffeine intake (24-hour recall), and smoking (never, past, current and pack-years). We calculated BMI from height and weight measured at the ALHS home visit. Individuals were classified as having cardiovascular disease if they answered ‘yes’ to either ever experienced heart failure (asked in ALHS) or ever experienced a stroke (asked at AHS Phase Three). Final models included all the aforementioned covariates except alcohol use, caffeine intake, or smoking because they did not separately change regression coefficients by at least 10%.

Analyses included the 1,569 individuals (98.3% of 1,596) with complete covariate data (234 cases of sleep apnea and 1,335 non-cases). A secondary analysis evaluated waist circumference, measured at the ALHS home visit, as an alternative adiposity adjustment variable to BMI (sleep apnea cases=227, non-cases=1,307).

In additional analyses, we compared the year of first pesticide exposure to onset of sleep apnea. We also examined effect modification, and interaction, separately by asthma status and personal protective equipment use. In addition to the uncorrected P values presented in the tables, we calculated False Discovery Rate adjusted P values (PFDR) for the primary analysis, accounting for 63 tests using the Benjamini-Hochberg method (24). Adjustment variables were the same as in the main analyses. We used SAS (SAS Institute Inc., Cary, NC, Version 9.3, except for tetrachoric correlations calculated using Version 9.4). Analyses used the following releases of the AHS data: P3REL201209.00, PIREL201209.00 and AHSREL201304.00.

Results

Nearly all participants were white (98.4%); few (<5%) were current smokers. Sleep apnea cases were slightly older than non-cases (Table 1). As expected, BMI was higher among cases (Table 1); the adjusted odds ratio (OR) per unit increase in BMI was 1.16 (95% Confidence Interval (CI) 1.13–1.19). Sleep apnea was more common among asthmatics (Table 1); adjusted OR:2.47, 95% CI 1.87–3.27. The 234 sleep apnea cases reported the following use of each of the queried treatments: CPAP (n=215, 91.9%), “surgery” (n=16, 6.8%), “bi-level” (n=23, 9.8%), “other oral device” (n=22, 9.4%); more than one treatment could be listed.

Table 1.

Characteristics of sleep apnea cases and controls in the ALHS

Sleep Apnea cases (n=234) Non-cases (n=1335)

Characteristic n (%)/mean (SD) n (%)/mean (SD)
Asthma
 No 113 (48.3) 934 (70.0)
 Yes 121 (51.7) 401 (30.0)
State of residence
 Iowa 176 (75.2) 924 (69.2)
 North Carolina 58 (24.8) 411 (30.8)
Cardiovascular Disease
 No 205 (87.6) 1292 (96.8)
 Yes 29 (12.4) 43 (3.2)
Hypertension
 No 113 (48.3) 855 (64.0)
 Yes 121 (51.7) 480 (36.0)
Diabetes
 No 186 (79.5) 1212 (90.8)
 Yes 48 (20.5) 123 (9.2)
Age at home visit (years) 64.7 (10.6) 63.2 (11.6)
Body Mass Index (BMI) 34.5 (6.1) 29.8 (5.6)

Definition of Abbreviation: ALHS = Agricultural Lung Health Study

We evaluated ever/never use of 63 pesticides in relation to sleep apnea. The 63 pesticides included 40 herbicides and plant growth regulators, 19 insecticides, 3 fungicides, and 1 rodenticide. Four pesticides were associated with sleep apnea at nominal P<0.05 (Table 2). Carbofuran, a carbamate pesticide, was the most statistically significant finding (P=0.0002) with the largest number (n=100) of exposed cases (OR:1.83, 95% CI 1.34–2.51) (Table 2). Among the three carbamate pesticides, only carbofuran gave P<0.05 but odds ratios for both aldicarb (OR:1.52, 95% CI 0.80–2.88) and carbaryl (OR:1.11, 95% CI 0.81–1.54) (Table 2) were also above one. Bifenthrin, a pyrethroid, was also positively associated with sleep apnea at P<0.05 but with wide confidence intervals reflecting only 5 exposed cases (OR:4.39, 95% CI 1.33–14.46, P=0.015). Two pesticides showed inverse associations at nominal P<0.05: picloram, an acetic acid herbicide (25 exposed cases, OR:0.61, 95% CI 0.38–1.00, P=0.048), and metalaxyl, a fungicide (34 exposed cases, OR: 0.59, 95%CI 0.38–0.92, P=0.020) (Table 2). When we control the false discovery rate among all 63 pesticides, only the association with carbofuran (PFDR=0.01) meets the PFDR<0.05 threshold. The PFDR values are very high for the associations with other three pesticides with uncorrected P<0.05 (PFDR:0.510 for picloram, 0.42 for both bifenthrin and metalaxyl).

Table 2.

Sleep apnea and pesticide use among male applicators in the ALHS*

Sleep Apnea (N=1569)
Cases (n=234) Non-cases (n=1335)

Pesticide Exposed, n (%) Exposed, n (%) OR 95% CI P-value
Herbicide
Acetic acid
 Clopyralid 23 (9.8) 109 (8.2) 1.09 0.63 1.87 0.765
 Flumetsulam 21 (9.0) 111 (8.3) 0.98 0.57 1.68 0.929
 Dicamba 137 (58.5) 736 (55.1) 1.08 0.76 1.53 0.681
 Picloram 25 (10.7) 204 (15.3) 0.61 0.38 1.00 0.048
Amide
 Dimethenamid 13 (5.6) 87 (6.5) 0.90 0.47 1.73 0.759
 Fomesafen 11 (4.7) 94 (7.0) 0.56 0.28 1.15 0.114
Anilide
 Sulfentrazone 8 (3.4) 44 (3.3) 1.34 0.58 3.13 0.495
 Mesotrione 18 (7.7) 151 (11.3) 0.76 0.43 1.32 0.323
Chloroacetanilide
 Acetochlor 33 (14.1) 215 (16.1) 0.69 0.44 1.08 0.101
 Alachlor 134 (57.3) 796 (59.6) 0.82 0.60 1.12 0.219
 Metolachlor 136 (58.1) 719 (53.9) 1.19 0.86 1.65 0.285
Cyclohexene oxime
 Clethodim 9 (3.8) 45 (3.4) 1.59 0.72 3.53 0.252
 Sethoxydim 46 (19.7) 318 (23.8) 0.82 0.57 1.20 0.311
Dinitroaniline
 Pendimethalin 102 (43.6) 594 (44.5) 0.99 0.73 1.35 0.970
 Trifluralin 116 (49.6) 716 (53.6) 0.83 0.60 1.14 0.251
Imidazolinone
 Imazaquin 40 (17.0) 199 (14.9) 1.11 0.74 1.67 0.614
 Imazethapyr 96 (41.0) 552 (41.3) 0.96 0.68 1.36 0.816
Nitrile
 Bromoxynil 53 (22.6) 307 (23.0) 0.95 0.65 1.38 0.778
Nitrophenyl ether
 Acifluorfen 24 (10.3) 194 (14.5) 0.77 0.47 1.25 0.284
 Lactofen 7 (3.0) 36 (2.7) 0.94 0.39 2.29 0.894
Organophosphorus
 Glufosinate Ammonium 19 (8.1) 111 (8.3) 0.95 0.55 1.67 0.869
 Glyphosate 210 (89.7) 1224 (91.7) 1.05 0.62 1.77 0.860
Oxazole
 Isoxaflutole 14 (6.0) 84 (6.3) 1.00 0.53 1.91 0.996
Protroleum products
 Petroleum Distillates 75 (32.0) 450 (33.7) 0.96 0.69 1.34 0.822
Phenoxy
 2,4-D 208 (88.9) 1138 (85.2) 1.58 0.96 2.60 0.073
 Fluazifop-butyl 34 (14.5) 191 (14.3) 1.23 0.80 1.91 0.349
 Fenoxaprop-p-ethyl 9 (3.8) 65 (4.9) 0.87 0.40 1.89 0.719
Pyridine
 Triclopyr 18 (7.7) 118 (8.8) 1.00 0.57 1.74 0.999
Quaternary ammonium
 Paraquat 48 (20.5) 295 (22.1) 1.15 0.78 1.69 0.492
Sulfonanilide
 Cloransulam-methyl 13 (5.6) 55 (4.1) 1.44 0.72 2.87 0.297
Triazine
 Atrazine 202 (86.3) 1087 (81.4) 1.54 0.97 2.43 0.065
 Simazine 18 (7.7) 95 (7.1) 1.16 0.65 2.06 0.622
Triazinone
 Metribuzin 100 (42.7) 602 (45.1) 0.82 0.60 1.14 0.242
Urea Substitute
 Chlorimuron Ethyl 82 (35.0) 491 (36.8) 0.96 0.69 1.32 0.782
 Nicosulfuron 38 (16.2) 172 (12.9) 1.50 0.97 2.32 0.068
 Rimsulfuron 16 (6.8) 72 (5.4) 1.49 0.81 2.74 0.198
 Thifensulfuron-methyl 10 (4.3) 92 (6.9) 0.67 0.32 1.39 0.281
Other
 Bentazon 60 (25.6) 356 (26.7) 0.95 0.67 1.36 0.790
 Clomazone 22 (9.4) 187 (14.0) 0.60 0.36 1.01 0.053
Plant Growth
Regulator

 Maleic Hydrazide 8 (3.4) 61 (4.6) 0.87 0.36 2.09 0.747
Insecticide

Biological
 Bacillus Thuringiensis 14 (6.0) 81 (6.1) 1.25 0.64 2.43 0.508
Carbamate
 Aldicarb 17 (7.3) 102 (7.6) 1.52 0.80 2.88 0.205
 Carbaryl 128 (54.7) 729 (54.6) 1.11 0.81 1.54 0.511
 Carbofuran 100 (42.7) 392 (29.4) 1.83 1.34 2.51 0.0002
Organochlorine
 Lindane 51 (21.8) 261 (19.5) 1.05 0.73 1.53 0.787
Organophosphate§
 Acephate 15 (6.4) 138 (10.3) 0.67 0.34 1.32 0.246
 Chlorpyrifos 111 (47.4) 672 (50.3) 0.90 0.66 1.23 0.513
 Diazinon 62 (26.5) 400 (30.0) 0.85 0.60 1.20 0.343
 Dimethoate 10 (4.3) 66 (4.9) 0.93 0.45 1.93 0.853
 Disulfoton 11 (4.7) 80 (6.0) 1.11 0.53 2.33 0.776
 Malathion 162 (69.2) 979 (73.3) 0.94 0.67 1.32 0.735
 Tebupirimfos 19 (8.1) 94 (7.0) 1.06 0.59 1.89 0.846
 Terbufos 124 (53.0) 579 (43.4) 1.34 0.97 1.85 0.072
Pyrethroid
 Bifenthrin 5 (2.1) 11 (0.82) 4.39 1.33 14.5 0.015
 Cyfluthrin 28 (12.0) 137 (10.3) 1.24 0.77 2.02 0.377
 Lambda Cyhalothrin 18 (7.7) 87 (6.5) 1.38 0.75 2.53 0.298
 Permethrin 31 (13.2) 140 (10.5) 1.49 0.93 2.38 0.098
 Tefluthrin 19 (8.1) 76 (5.7) 1.36 0.75 2.48 0.314
Other
 Fly Spray 7 (3.0) 22 (1.6) 1.89 0.72 4.97 0.197
Fungicide

 Captan 34 (14.5) 174 (13.0) 1.07 0.69 1.67 0.758
 Chlorothalonil 15 (6.4) 99 (7.4) 0.99 0.52 1.89 0.975
 Metalaxyl 34 (14.5) 310 (23.2) 0.59 0.38 0.92 0.020
Rodenticide

 Warfarin 5 (2.1) 46 (3.4) 0.41 0.14 1.17 0.094

Definition of Abbreviation: ALHS = Agricultural Lung Health Study

*

Adjusted for age, state, BMI, diabetes, hypertension, asthma, and cardiovascular disease.

OR: Odds Ratio, 95 % CI: 95% Confidence Interval

P values are uncorrected. With either Bonferroni correction for 63 tests or control of the false discovery rate at 5%, only the association with carbofuran would be considered statistically significant.

§

Organophosphorus Insecticide is a different chemical class than Organophosphorus Herbicide.

Although we hypothesized that organophosphate insecticides might be related to sleep apnea because, like carbamates, they inhibit acetylcholinesterase, none among eight were associated at nominal P <0.05 (Table 2). Among the three with ORs>1.00 (disulfoton, tebupirimfos and terbufos), terbufos was the most strongly associated with sleep apnea (124 exposed cases, OR:1.34, 95% CI 0.97–1.85, P=0.072, PFDR=0.51).

Participants were queried on prior AHS questionnaires about “unusually high personal exposure” incidents. There were 334 incidents reported by 298 participants. Deleting the 7 participants reporting a carbofuran incident (1 case and 6 non-cases) changed the OR only from 1.83 to 1.84 (95% CI 1.34–2.52).

For carbofuran, all 96 (of 100) sleep apnea cases with available timing data reported first exposure before onset of sleep apnea; use began a median of 26.5 years before (interquartile range=19.5–32.5). We had data on lifetime days of use for carbofuran (Table 3). The positive association with carbofuran did not attenuate at higher exposures (Ptrend=0.003).

Table 3.

Sleep apnea in relation to lifetime days of use of carbofuran among male applicators in the ALHS*

Sleep Apnea (N=1569)

Cases (n=234) Non-cases (n=1335)

Lifetime days of use Exposed, n (%) Exposed, n (%) OR 95% CI p-value§ Trend p-value§
 Never use 126 (57.8) 859 (69.5) ref ref ref ref
 < 14.5 33 (15.1) 144 (11.7) 1.69 1.06 2.67 0.03
 ≥14.5 to <38.75 26 (11.9) 115 (9.3) 1.71 1.03 2.83 0.04
 ≥38.75 33 (15.1) 117 (9.5) 1.75 1.08 2.82 0.02 0.003
 Missing 16 100

Definition of Abbreviation: ALHS = Agricultural Lung Health Study

*

Adjusted for age, state, BMI, asthma, cardiovascular disease, hypertension, diabetes

OR: odds Ratio

95% CI: 95% confidence interval

§

P-value, uncorrected

Smoking was not significantly associated with sleep apnea (crude OR:0.59, 95% CI 0.27–1.31) in our population with few current smokers, nor was current alcohol intake (crude OR:1.18, 95% CI 0.85–1.64). Therefore, neither were included in our primary models. However, adjustment did not materially alter results. The OR for carbofuran was 1.84 (95 % CI 1.34–2.53) after smoking adjustment and remained 1.83 (95% CI:1.33–2.51) after alcohol adjustment.

We adjusted for BMI because of its established relationship with sleep apnea. Waist circumference, a more specific index of central obesity, was too highly correlated with BMI (Pearson correlation=0.88) to include both in models. Results were very similar when waist circumference replaced BMI in models for any of the four pesticides associated with sleep apnea at P<0.05; OR for carbofuran was 1.81 (95% CI 1.31–2.49) versus 1.83 with BMI adjustment. We saw no consistent effect measure modification by use of personal protective equipment, defined by use of respirator or dust mask. Likewise, results did not differ materially by asthma status (data not shown).

Discussion

In a cohort of male pesticide applicators, primarily farmers, we examined 63 pesticides in relation to sleep apnea. The most statistically significant association was for the carbamate pesticide carbofuran (OR:1.83, 95% CI 1.34–2.51, P=0.0002). We confirmed that exposure to carbofuran began before the reported age of onset of sleep apnea for all cases with information on timing of first exposure.

The primary mode of action of carbofuran, like other carbamates and organophosphates, is via inhibition of the enzyme acetylcholinesterase. Organophosphates are regarded as irreversible inhibitors of acetylcholinesterase, whereas carbamates, including carbofuran, are slowly reversible inhibitors. With either, acetylcholine accumulates at nerve junctions, leading to overstimulation of acetylcholine receptors with later toxicity and potential perturbation of the sympathetic, parasympathetic, and peripheral nervous systems (4, 25). Acetylcholinesterase acts on cholinergic neurons involved in control of breathing in the sleep-wake cycle (1). Poisoning by any pesticides with this mechanism of action could result in respiratory depression (4, 26). Thus, carbamates could play a role in the onset and/or progression of central sleep apnea. Carbofuran can influence neurologic function via mechanisms other than acetylcholinesterase inhibition. In fish, carbofuran impacts levels of other neurotransmitters including dopamine, norepinephrine and serotonin. The degree and direction of these changes varies by brain region (27). Behavioral changes observed in fish after carbofuran exposure may be more sensitive indicators of neurotoxicity than altered brain catecholamine levels (28). Carbofuran increased various oxidative stress parameters in the rat brain and produced motor and cognitive deficits; administration of the antioxidant N-acetylcysteine reduced these effects (29). Of note, recently a computational approach has shown that carbofuran mimics melatonin, a critical hormone in the sleep-wake cycle, and can bind to its receptor (16). The increasing data implicating melatonin, a hormone crucial in the regulation of the sleep-wake cycle, in the sleep apnea or its severity (17, 18, 30) together with the ability of carbofuran to mimic melatonin (16) provides an alternative or complementary mechanism for an impact of carbofuran exposure on sleep apnea.

Because obstructive sleep apnea is much more common than central, most of the sleep apnea in our study likely has a strong obstructive component. The etiology of obstructive and central sleep apnea is often mixed, and a putative cause of central sleep apnea could be synergistic with causes of the obstructive disorder. The overlap between central sleep apnea and obstructive sleep apnea suggests that some common mechanisms are likely involved (1).

Ideally, we would have classified sleep apnea based on objective measures such as polysomnography. Instead, we identified sleep apnea from self-report of doctor diagnosis plus treatment. Requiring treatment in the definition increases reliability of this self-reported outcome (22). Because bias in estimating relative measures of association increases with a case definition that is less specific but more sensitive (31), requiring treatment in the definition increases specificity of the outcome reducing potential bias. Sleep apnea prevalence as defined in our study of older men (mean age 63.4 years) was relatively high at 14.8%; reported prevalence of obstructive sleep apnea in US men aged 45–64 is 4.7% (5). Our higher prevalence of sleep apnea reflects, in part, oversampling of asthmatics; increased rates of sleep apnea reported in asthmatics were confirmed in our analysis (32). We also had a relatively high prevalence of sleep apnea reported by non-cases (10.8%). However, based on polysomnography, much sleep apnea in the general population is undiagnosed making the true prevalence uncertain (22). Because we used self-reported sleep apnea rather than polysomnography our non-case group likely includes some individuals with undiagnosed sleep apnea; this misclassification will tend to attenuate associations with pesticide exposure rather than result in a spurious positive association. Alternatively, if likelihood of diagnosis with and treatment for sleep apnea is related to pesticide use, bias away from the null could result. Sleep apnea risk factors such as higher BMI and cardiovascular disease increase likelihood of referral for evaluation and thus physician diagnosis (22, 33). If these factors are related to prior pesticide use, confounding could occur; however, we adjusted for both.

The use of self-reported pesticide exposure creates the possibility of exposure misclassification. Nonetheless, data from the parent AHS supports the validity of self-reporting in our study population. Few AHS pesticide applicators self-reported a decade of first use inconsistent with the year a pesticide was first registered for use in the US (34). Overestimation of use duration was very low for carbofuran (<1%), our primary finding (34). Among orchardists, repeatability of reports of ever use approximately 20 years after initial report was found to be sufficiently accurate for epidemiological analyses, especially for more commonly used pesticides (35).

Our study has other limitations. With 234 cases, few were exposed to some individual pesticides. Lifetime days of use information, available for some pesticides, was likely underestimated because it was collected on the first AHS questionnaire. However, that questionnaire was completed prior to the reported year of sleep apnea onset for nearly all cases (92%) providing prospective data for this analysis. Because the response rate for entry into the ALHS was about 50%, selection bias is possible if non-response was jointly related to sleep apnea diagnosis and pesticide use. Earlier questionnaires did not query sleep apnea so we cannot estimate the response rate with respect to this outcome. However, sleep apnea is more common in asthmatics and the response rate was very similar by asthma status (20). Using asthma as a surrogate outcome to assess selection bias, it is reassuring that the association between asthma and carbofuran is very similar among all 23,498 male applicator respondents to the AHS Phase Three questionnaire from whom ALHS participants were sampled, (OR:1.09, 95% CI 0.97–1.23) and in ALHS participants (OR:1.18, 95% CI 0.95–1.47).

Lifetime days of use of carbofuran varied relatively little and odds ratios for sleep apnea were elevated at the lowest tertile of exposure (<14.5 lifetime days). Even if we underestimated lifetime exposure, we do not know if exposure at this level if sufficient to induce chronic effects on control of breathing in sleep apnea.

Our study has several strengths. We could assess temporality of sleep apnea onset in relation to first exposure to specific pesticides. For carbofuran, first use preceded diagnosis for all cases with temporal information. Use of specific pesticides was much higher in our farming population than in the general population, thereby increasing power. We had some data to evaluate dose-response with cumulative lifetime days of pesticide exposure and data on pesticide poisoning events. We also could adjust for various potential confounders including BMI and waist circumference based on objective measurements.

In 2009, the US EPA cancelled the use of carbofuran on crops for human or animal consumption based on evidence of toxicity (36). Canada and the European Union have also cancelled its use, but it is still employed in some other countries. US EPA classifies carbofuran as a Toxicity Category One pesticide, the most toxic category. Because of the steep exposure-response curve, small differences in exposure may lead to adverse effects and concern has been raised, especially for children, due to residual carbofuran in the food supply (36).

We found little evidence of association between sleep apnea and organophosphates; however, since the 1990s, when our cohort was enrolled, carbamates have been the most commonly used pesticides, largely replacing organophosphates. Before cancellation, carbofuran was the most commonly used carbamate in US agriculture.

Our motivating hypothesis was based on acetylcholinesterase inhibition by organophosphates and carbamates. However, because other mechanisms may be involved in neurotoxicity of these pesticide classes and others, we examined all 63 individual pesticides (15, 29, 37). We note that about 3 of 63 tests would be expected to result in P<0.05 by chance alone and we identified four, including the carbamate, carbofuran (P=0.0002). We saw modest correlation of ever use among the 63 pesticides: 18% of all tetrachoric correlations were >0.4; Bonferroni correction for multiple testing would be conservative, especially with positively correlated tests, increasing the chance of false negatives. Carbofuran would pass a Bonferroni-adjusted critical P value of 0.05/63=0.0008. However, similar conclusions are obtained when we control the false discovery rate across all 63 pesticides using the Benjamini-Hochberg procedure, which is less conservative than a Bonferroni correction; only the association with carbofuran (PFDR=0.01) meets a 0.05 PFDR threshold whereas the other three pesticides with uncorrected P<0.05 for association with sleep apnea have high PFDR values (0.42–0.51).

Conclusions

We conducted the first epidemiological study investigating the association of pesticide exposure and sleep apnea. Our results in a US male farming population suggests that exposure to carbofuran is positively associated with sleep apnea.

Acknowledgments

This work was supported by the intramural research program of the NIH, National Institute of Environmental Health Sciences (NIEHS) (Z01-ES049030 and ZO1-ES102385) and National Cancer Institute (Z01-CP010119). This work was also supported in part by American Recovery and Reinvestment Act (ARRA) funds through NIEHS contract number NO1-ES-55546. We thank the numerous study staff at Social & Scientific Systems, Inc. who played a role in the data collection and Dr. Marie Richards of Westat for computational assistance. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health (NIOSH). Mention of any company or product does not constitute endorsement by NIOSH.

Footnotes

Competing Financial Interests: None

Declaration of Interest: The authors declare no conflicts.

Disclaimers: The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health (NIOSH). Mention of any company or product does not constitute endorsement by NIOSH.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010;90:47–112. doi: 10.1152/physrev.00043.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.King ED, O’Donnell CP, Smith PL, Schwartz AR. A model of obstructive sleep apnea in normal humans. Role of the upper airway. Am J Respir Crit Care Med. 2000;161:1979–1984. doi: 10.1164/ajrccm.161.6.9904096. [DOI] [PubMed] [Google Scholar]
  • 3.Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med. 2002;165:1217–1239. doi: 10.1164/rccm.2109080. [DOI] [PubMed] [Google Scholar]
  • 4.Colovic MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase inhibitors: pharmacology and toxicology. Curr Neuropharmacol. 2013;11:315–335. doi: 10.2174/1570159X11311030006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Bixler EO, Vgontzas AN, Ten Have T, Tyson K, Kales A. Effects of age on sleep apnea in men: I. Prevalence and severity. Am J Respir Crit Care Med. 1998;157:144–148. doi: 10.1164/ajrccm.157.1.9706079. [DOI] [PubMed] [Google Scholar]
  • 6.Eckert DJ, Jordan AS, Merchia P, Malhotra A. Central sleep apnea: Pathophysiology and treatment. Chest. 2007;131:595–607. doi: 10.1378/chest.06.2287. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Weinreich G, Wessendorf TE, Pundt N, Weinmayr G, Hennig F, Moebus S, Mohlenkamp S, Erbel R, Jockel KH, Teschler H, Hoffmann B Heinz Nixdorf Recall study g. Association of short-term ozone and temperature with sleep disordered breathing. Eur Respir J. 2015;46:1361–1369. doi: 10.1183/13993003.02255-2014. [DOI] [PubMed] [Google Scholar]
  • 8.Zanobetti A, Redline S, Schwartz J, Rosen D, Patel S, O’Connor GT, Lebowitz M, Coull BA, Gold DR. Associations of PM10 with sleep and sleep-disordered breathing in adults from seven U.S. urban areas. Am J Respir Crit Care Med. 2010;182:819–825. doi: 10.1164/rccm.200912-1797OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Glaser MS, Shah N, Webber MP, Zeig-Owens R, Jaber N, Appel DW, Hall CB, Weakley J, Cohen HW, Shulman L, Kelly K, Prezant D. Obstructive sleep apnea and World Trade Center exposure. J Occup Environ Med. 2014;56(Suppl 10):S30–34. doi: 10.1097/JOM.0000000000000283. [DOI] [PubMed] [Google Scholar]
  • 10.Godderis L, Dours G, Laire G, Viaene MK. Sleep apnoeas and neurobehavioral effects in solvent exposed workers. Int J Hyg Environ Health. 2011;214:66–70. doi: 10.1016/j.ijheh.2010.08.006. [DOI] [PubMed] [Google Scholar]
  • 11.Ulfberg J, Carter N, Talback M, Edling C. Occupational exposure to organic solvents and sleep-disordered breathing. Neuroepidemiology. 1997;16:317–326. doi: 10.1159/000109704. [DOI] [PubMed] [Google Scholar]
  • 12.Rauh VA, Garcia WE, Whyatt RM, Horton MK, Barr DB, Louis ED. Prenatal exposure to the organophosphate pesticide chlorpyrifos and childhood tremor. Neurotoxicology. 2015;51:80–86. doi: 10.1016/j.neuro.2015.09.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Stallones L, Beseler C. Pesticide illness, farm practices, and neurological symptoms among farm residents in Colorado. Environ Res. 2002;90:89–97. doi: 10.1006/enrs.2002.4398. [DOI] [PubMed] [Google Scholar]
  • 14.Gaspari RJ, Paydarfar D. Dichlorvos-induced central apnea: effects of selective brainstem exposure in the rat. Neurotoxicology. 2011;32:206–214. doi: 10.1016/j.neuro.2011.01.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Costa LG, Giordano G, Guizzetti M, Vitalone A. Neurotoxicity of pesticides: a brief review. Front Biosci. 2008;13:1240–1249. doi: 10.2741/2758. [DOI] [PubMed] [Google Scholar]
  • 16.Popovska-Gorevski M, Dubocovich ML, Rajnarayanan RV. Carbamate Insecticides Target Human Melatonin Receptors. Chem Res Toxicol. 2017 doi: 10.1021/acs.chemrestox.6b00301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Butler MP, Smales C, Wu H, Hussain MV, Mohamed YA, Morimoto M, Shea SA. The Circadian System Contributes to Apnea Lengthening across the Night in Obstructive Sleep Apnea. Sleep. 2015;38:1793–1801. doi: 10.5665/sleep.5166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Reutrakul S, Siwasaranond N, Nimitphong H, Saetung S, Chirakalwasan N, Chailurkit LO, Srijaruskul K, Ongphiphadhanakul B, Thakkinstian A. Associations between nocturnal urinary 6-sulfatoxymelatonin, obstructive sleep apnea severity and glycemic control in type 2 diabetes. Chronobiol Int. 2017;34:382–392. doi: 10.1080/07420528.2016.1278382. [DOI] [PubMed] [Google Scholar]
  • 19.Alavanja MC, Sandler DP, McMaster SB, Zahm SH, McDonnell CJ, Lynch CF, Pennybacker M, Rothman N, Dosemeci M, Bond AE, Blair A. The Agricultural Health Study. Environ Health Perspect. 1996;104:362–369. doi: 10.1289/ehp.96104362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.House JS, Wyss AB, Hoppin JA, Richards M, Long S, Umbach DM, Henneberger PK, Beane Freeman LE, Sandler DP, Long O’Connell E, Barker-Cummings C, London SJ. Early-life farm exposures and adult asthma and atopy in the Agricultural Lung Health Study. J Allergy Clin Immunol. 2016 doi: 10.1016/j.jaci.2016.09.036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Carnes MU, Hoppin JA, Metwali N, Wyss AB, Hankinson JL, O’Connell EL, Richards M, Long S, Beane Freeman LE, Sandler DP, Henneberger PK, Barker-Cummings C, Umbach DM, Thorne PS, London SJ. House Dust Endotoxin Levels Are Associated with Adult Asthma in a U.S. Farming Population. Ann Am Thorac Soc. 2016 doi: 10.1513/AnnalsATS.201611-861OC. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Young T, Evans L, Finn L, Palta M. Estimation of the clinically diagnosed proportion of sleep apnea syndrome in middle-aged men and women. Sleep. 1997;20:705–706. doi: 10.1093/sleep/20.9.705. [DOI] [PubMed] [Google Scholar]
  • 23.Hoppin JA, Long S, Umbach DM, Lubin JH, Starks SE, Gerr F, Thomas K, Hines CJ, Weichenthal S, Kamel F, Koutros S, Alavanja M, Beane Freeman LE, Sandler DP. Lifetime organophosphorous insecticide use among private pesticide applicators in the Agricultural Health Study. J Expo Sci Environ Epidemiol. 2012;22:584–592. doi: 10.1038/jes.2012.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003;19:368–375. doi: 10.1093/bioinformatics/btf877. [DOI] [PubMed] [Google Scholar]
  • 25.Kubin L, Fenik V. Pontine cholinergic mechanisms and their impact on respiratory regulation. Respir Physiol Neurobiol. 2004;143:235–249. doi: 10.1016/j.resp.2004.04.017. [DOI] [PubMed] [Google Scholar]
  • 26.Gammon DW, Liu Z, Becker JM. Carbofuran occupational dermal toxicity, exposure and risk assessment. Pest Manag Sci. 2012;68:362–370. doi: 10.1002/ps.2270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Gopal K, Ram M. Alteration in the neurotransmitter levels in the brain of the freshwater snakehead fish (Channa punctatus) exposed to carbofuran. Ecotoxicology. 1995;4:1–4. doi: 10.1007/BF00350646. [DOI] [PubMed] [Google Scholar]
  • 28.Bretaud S, Saglio P, Saligaut C, Auperin B. Biochemical and behavioral effects of carbofuran in goldfish (Carassius auratus) Environ Toxicol Chem. 2002;21:175–181. [PubMed] [Google Scholar]
  • 29.Kamboj A, Kiran R, Sandhir R. Carbofuran-induced neurochemical and neurobehavioral alterations in rats: attenuation by N-acetylcysteine. Exp Brain Res. 2006;170:567–575. doi: 10.1007/s00221-005-0241-5. [DOI] [PubMed] [Google Scholar]
  • 30.Zirlik S, Hildner KM, Targosz A, Neurath MF, Fuchs FS, Brzozowski T, Konturek PC. Melatonin and omentin: influence factors in the obstructive sleep apnoea syndrome? J Physiol Pharmacol. 2013;64:353–360. [PubMed] [Google Scholar]
  • 31.Brenner H. Correcting for exposure misclassification using an alloyed gold standard. Epidemiology. 1996;7:406–410. doi: 10.1097/00001648-199607000-00011. [DOI] [PubMed] [Google Scholar]
  • 32.Teodorescu M, Barnet JH, Hagen EW, Palta M, Young TB, Peppard PE. Association between asthma and risk of developing obstructive sleep apnea. JAMA. 2015;313:156–164. doi: 10.1001/jama.2014.17822. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Franklin KA, Lindberg E. Obstructive sleep apnea is a common disorder in the population-a review on the epidemiology of sleep apnea. J Thorac Dis. 2015;7:1311–1322. doi: 10.3978/j.issn.2072-1439.2015.06.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Hoppin JA, Yucel F, Dosemeci M, Sandler DP. Accuracy of self-reported pesticide use duration information from licensed pesticide applicators in the Agricultural Health Study. J Expo Anal Environ Epidemiol. 2002;12:313–318. doi: 10.1038/sj.jea.7500232. [DOI] [PubMed] [Google Scholar]
  • 35.Engel W, Vogt A, Batsford SR. Validity of prior absorption of serum samples with Reiter’s spirochetes in serological diagnosis of Borrelia burgdorferi infections. Eur J Clin Microbiol Infect Dis. 2000;19:960–963. doi: 10.1007/s100960000398. [DOI] [PubMed] [Google Scholar]
  • 36.Agency EP. Carbofuran; Product Cancellation Order. 2009 [cited 2016 October 18]. Available from: https://www.federalregister.gov/documents/2009/03/18/E9-5833/carbofuran-product-cancellation-order.
  • 37.Gupta A, Agarwal R, Shukla GS. Functional impairment of blood-brain barrier following pesticide exposure during early development in rats. Hum Exp Toxicol. 1999;18:174–179. doi: 10.1177/096032719901800307. [DOI] [PubMed] [Google Scholar]

RESOURCES